E
Elizabeth R. Unger
Researcher at Centers for Disease Control and Prevention
Publications - 349
Citations - 20304
Elizabeth R. Unger is an academic researcher from Centers for Disease Control and Prevention. The author has contributed to research in topics: Population & Cervical cancer. The author has an hindex of 62, co-authored 329 publications receiving 18259 citations. Previous affiliations of Elizabeth R. Unger include University of Chicago & Karolinska Institutet.
Papers
More filters
Journal Article
Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
Lauri E. Markowitz,Eileen F. Dunne,Mona Saraiya,Herschel W. Lawson,Harrell W. Chesson,Elizabeth R. Unger +5 more
TL;DR: The first statement by the Advisory Committee on Immunization Practices (ACIP) on the use of a quadrivalent human papillomavirus (HPV) vaccine was made by the U.S. Food and Drug Administration on June 8, 2006 as mentioned in this paper.
Journal ArticleDOI
Prevalence of HPV Infection Among Females in the United States
Eileen F. Dunne,Elizabeth R. Unger,Maya R. Sternberg,Geraldine M. McQuillan,David C. Swan,Sonya Patel,Lauri E. Markowitz +6 more
TL;DR: The data indicate that the burden of prevalent HPV infection among females was greater than previous estimates and was highest among those aged 20 to 24 years, however, the prevalence of HPV vaccine types was relatively low.
Journal Article
Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices.
Emiko Petrosky,Joseph A. Bocchini,Susan Hariri,Harrell W. Chesson,C. Robinette Curtis,Mona Saraiya,Elizabeth R. Unger,Lauri E. Markowitz +7 more
TL;DR: Evidence considered by ACIP in recommending 9vHPV as one of three HPV vaccines that can be used for vaccination is summarized and recommendations for vaccine use are provided.
Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP).
Lauri E. Markowitz,Eileen F. Dunne,Mona Saraiya,Harrell W. Chesson,Curtis Cr,Julianne Gee,Joseph A. Bocchini,Elizabeth R. Unger +7 more
TL;DR: This report summarizes the epidemiology of human papillomavirus (HPV) and associated diseases, describes the licensed HPV vaccines, provides updated data from clinical trials and postlicensure safety studies, and compiles recommendations from CDC's Advisory Committee on Immunization Practices (ACIP) for use of HPV vaccines.
Journal ArticleDOI
US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines.
Mona Saraiya,Elizabeth R. Unger,Trevor D. Thompson,Charles F. Lynch,Brenda Y. Hernandez,Christopher Lyu,Martin Steinau,Meg Watson,Edward J. Wilkinson,Claudia Hopenhayn,Glenn Copeland,Wendy Cozen,Edward S. Peters,Youjie Huang,Maria Sibug Saber,Sean F. Altekruse,Marc T. Goodman +16 more
TL;DR: In the United States, current vaccines will reduce most HPV-associated cancers; a smaller additional reduction would be contributed by the new 9-valent vaccine.